texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician

Share:

 
 

San Antonio Clinical Trials

Texas Oncology cancer centers in San Antonio participate in clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the San Antonio area, you may be able to take part in these innovative clinical trials.

Our San Antonio cancer centers offer several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. For example, the trial might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. Often, these trials involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies. They involve current cancer patients.

To review recent publications related to cancer research conducted by our physician, please click here.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the San Antonio area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which may take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. If you’re interested in participating in a clinical trial, view the list of open San Antonio trials below and talk to you doctor to determine which one may be right for you.

Cancer Research Making a Difference

Advancements in cancer research are not only making headlines but also making treatment – and life – better for cancer patients. Dr. Sharon Wilks, Texas Oncology–San Antonio Northeast shares perspectives on noteworthy outcomes from breakthrough cancer research. Learn More.

Clinical Trial Principal Investigators in San Antonio

Biliary Cancer

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Bladder Cancer

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Breast Cancer

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph2 alpelisib+fulves/letrozole HR+ HER2- View

Description: BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Cervical Cancer

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Epithelial Carcinomas

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-San Antonio Northeast

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-San Antonio Medical Center

Fallopian Tube Cancer

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Hematologic

Title: PNH Registry View

Description: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (M07-001)

Indication: Hematologic

Location: Texas Oncology-New Braunfels

Phase: IV

Title: PNH Registry View

Description: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (M07-001)

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Leukemia

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ublit +/- Umbra (TGR-1202) View

Description: An Open Label Compassionate Use Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination with other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study (UTX-TGR-501)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ublit +/- Umbra (TGR-1202) View

Description: An Open Label Compassionate Use Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination with other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study (UTX-TGR-501)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Lung Cancer

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Lymphomas

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Melanoma

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Northeast

Phase: II

Myelodysplastic Syndrome

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Myelomas

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-New Braunfels

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Ovarian Cancer

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Peritoneal Cancer

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Prostate Cancer

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Renal Cancer

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Solid Tumors

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Urothelial Cancer

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Texas Oncology-New Braunfels

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: PNH Registry View

Description: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (M07-001)

Indication: Hematologic

Location: Texas Oncology-New Braunfels

Phase: IV

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: II

Title: Ublit +/- Umbra (TGR-1202) View

Description: An Open Label Compassionate Use Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination with other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study (UTX-TGR-501)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-New Braunfels

Phase: IV

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Texas Oncology-San Antonio Downtown

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Texas Oncology-San Antonio Medical Center

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-San Antonio Medical Center

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PNH Registry View

Description: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (M07-001)

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ublit +/- Umbra (TGR-1202) View

Description: An Open Label Compassionate Use Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination with other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study (UTX-TGR-501)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Texas Oncology-San Antonio Northeast

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-San Antonio Northeast

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph2 alpelisib+fulves/letrozole HR+ HER2- View

Description: BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Texas Oncology-San Antonio Stone Oak

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

No Phase

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-San Antonio Northeast

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-San Antonio Medical Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase I

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: Ph1 Solid tumors, RCC, mCRPC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Phase I/II

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: I/II

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Phase II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 alpelisib+fulves/letrozole HR+ HER2- View

Description: BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph2 Cervical 2L (RaPiDS) View

Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Tepotinib stage IIIB/IV NSCLC w/ METex14 View

Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Melanoma

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Ph2 Anti-PD1 INCMGA00012 Solid Tumors View

Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Phase III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3b Venetoclax AML View

Description: A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ublit +/- Umbra (TGR-1202) View

Description: An Open Label Compassionate Use Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination with other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study (UTX-TGR-501)

Indication: Leukemia

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ublit +/- Umbra (TGR-1202) View

Description: An Open Label Compassionate Use Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination with other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study (UTX-TGR-501)

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-New Braunfels

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02) View

Description: (Amgen 20180015) A Randomized, Open-label, Phase 3 StudyComparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-New Braunfels

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Phase IV

Title: PNH Registry View

Description: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (M07-001)

Indication: Hematologic

Location: Texas Oncology-New Braunfels

Phase: IV

Title: PNH Registry View

Description: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (M07-001)

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-New Braunfels

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: STAR PhIV Gazyva, Adv FL View

Description: (MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-New Braunfels

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: IV